Free tool
FAERS Monitor: Blenrep
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761440 or its brand name (Blenrep, Belantamab Mafodotin-Blmf). Reports on generic versions are filed under their own applications.
Reports
3,107
Serious
2,738
88% of reports
Hospitalization
793
Death reported
1,042
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- keratopathy856
- visual acuity reduced800
- death586
- plasma cell myeloma455
- dry eye404
- night blindness317
- vision blurred204
- photophobia189
- foreign body sensation in eyes186
- ocular toxicity168
- visual impairment131
- punctate keratitis130
- pneumonia126
- thrombocytopenia124
- corneal epithelial microcysts122
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 185 |
| 2021 | 776 |
| 2022 | 1,149 |
| 2023 | 270 |
| 2024 | 82 |
| 2025 | 160 |
| 2026 | 482 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| corneal epithelial microcystsSignal | 122 | 18368.8 | 13073.9 | 598,858 |
| keratopathySignal | 856 | 7977.6 | 7273.6 | 3,131,953 |
| night blindnessSignal | 317 | 1670.1 | 1484.6 | 422,920 |
| ocular toxicitySignal | 168 | 1216.1 | 1035.8 | 171,909 |
| punctate keratitisSignal | 130 | 1117.8 | 931.6 | 123,557 |
| foreign body sensation in eyesSignal | 186 | 203.4 | 176.6 | 36,189 |
| visual acuity reducedSignal | 800 | 167.1 | 157.2 | 128,921 |
| plasma cell myelomaSignal | 455 | 79.9 | 73.3 | 35,008 |
| photophobiaSignal | 189 | 68.7 | 59.8 | 12,425 |
| dry eyeSignal | 404 | 55.2 | 50.4 | 21,335 |
| vision blurredSignal | 204 | 10.1 | 8.8 | 1,666 |
| thrombocytopeniaSignal | 124 | 7.5 | 6.3 | 697 |
| visual impairmentSignal | 131 | 7.2 | 6.1 | 692 |
| deathSignal | 586 | 4.6 | 4.3 | 1,721 |
| pneumoniaSignal | 126 | 2.6 | 2.2 | 128 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.